<DOC>
	<DOCNO>NCT01036022</DOCNO>
	<brief_summary>This study first-time-in-patient trial GSK1399686 , novel locally-acting anti-inflammatory compound , aim obtain initial information tolerability , safety , pharmacokinetics ( include concentration colon mucosa ) anti-inflammatory activity GSK1399686 upon oral dose patient active ulcerative colitis . The study design randomize , double-blind , double-dummy , placebo-controlled , sequential dose escalate trial , active control ( ASACOL ) group internal control . Up three cohort ( Cohorts 1-3 ) , consist approximately 20 patient mild-moderately active ulcerative colitis limit rectum , include , one dose level GSK1399686 test . Within cohort , patient randomize 3:1:1 ratio receive GSK1399686 ( daily 4 week , follow 2 week dose placebo ) , placebo , ASACOL ( t.i.d . 6 week ) , respectively . An interim analysis fecal marker disease activity data perform end Cohort 3 . Based upon result , study may stop continue recruit either Cohort 4 ( data additional dose level would warrant establish clarify dose-response relationship ) , case robust efficacy signal dose level previously study , Cohort 5 ( expand sample size give dose level order evaluate efficacy GSK1399686 ) . The number patient randomization allocation ratio may alter Cohort 5 may include active control arm . If Cohort 4 initiate upon interim analysis , second interim analysis may perform end Cohort 4 , ass whether progression Cohort 5 ( define ) would justifiable .</brief_summary>
	<brief_title>Effect GSK1399686 Patients With Mild Moderately Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . Male female nonchildbearing potential 18 65 year age inclusive . 2 . Presence mildtomoderately active ulcerative colitis spread beyond rectum evidence clinical sign endoscopy . 3 . UCDAI score 410 ( inclusive ) rectal bleed score ≥ 1 , endoscopy score ≥ 1 Physician 's rating disease activity &lt; 3 . 4 . Body weight &gt; = 50 kg BMI within range 18.529.9 kg/m2 ( inclusive ) . 5 . Capable give write informed consent , include compliance requirement restriction list consent form 1 . History sensitivity component study medication , history hypersensitivity ACTH , history drug allergy , opinion Investigator , contraindicate patient 's participation study . 2 . History renal sensitivity 5ASA presence nephritis , nephropathia renal function impairment . 3 . Presence history asthma presence history serious allergic disorder . 4 . Presence history chronic liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 5 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . 6 . Presence significant hematologic disorder , significant bleed immune system disorder . 7 . QTcB QTcF &gt; 450 msec ; QTc &gt; 480 msec patient Bundle Branch Block , base average QTc value triplicate ECGs , first ECG show abnormal value . 8 . Presence significant cardiac , pulmonary , metabolic infectious disease mental disorder , opinion Investigator , represent unacceptable safety risk participation trial . 9 . History malignant neoplastic disease within past 5 year localize basal cell skin cancer , squamous cell skin cancer cancer situ resect . 10 . History regular alcohol consumption within 6 month study presence recreational drug abuse dependence . 11 . Presence infectious colitis evidence stool culture positive enteric pathogen positive Clostridium difficile cytotoxin assay . 12 . Suspicion Crohn 's disease , indeterminate colitis , microscopic colitis , ischaemic colitis radiationinduced colitis , base medical history , endoscopy and/or histological finding . 13 . Bowel surgery within last 12 month . 14 . Treatment oral aminosalicylates dose ≥ 2.4 g/day and/or topical aminosalicylates dose within 2 week prior Day 1 visit . 15 . Treatment systemic topical corticosteroid within 4 week prior Day 1 visit . 16 . Treatment TNFα inhibitor biologics within 2 month prior Day 1 visit . 17 . Treatment immunosuppressant ( azathioprine 6mercaptopurine ) , initiate within 3 month prior Day 1 visit , change term drug dose within 3 month prior Day 1 visit . 18 . Regular use probiotic prebiotic preparation , initiate within 4 week prior Day 1 visit . 19 . Regular daily use nonsteroidal antiinflammatory drug ( NSAIDs ) , except low dose aspirin ( 325 mg/day ) cardioprotection , within 7 day prior Day 1 visit . 20 . Treatment medication know strong inducer CYP3A4/5 ( e.g . carbamezipine , phenobarbital , phenytoin , rifabutin , rifampin , troglitazone ) regular use St. John 's Wort within 14 day prior Day 1 visit . 21 . Treatment medication know strong inhibitor CYP3A4/5 ( e.g . ketoconazole , itraconazole , fluconazole , mibefradil , clarithromycin , erythromycin , diltiazem , verapamil ) , regular use grapefruit juice within 7 day prior Day 1 visit . 22 . Treatment medication know sensitive CYP3A4 substrates narrow therapeutic index ( e.g . alfentanil , astemizole , cisapride , cyclosporine , diergotamine , ergotamine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus , terfenadine ) within 7 day prior Day 1 visit . 23 . Participation clinical trial treatment investigational product within following time period prior Day 1 visit : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 24 . Prior enrolment present trial . For Canadian site : 25 . Patients exist gastric duodenal ulcer . 26 . Patients urinary tract obstruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>GSK1399686</keyword>
	<keyword>mesalazine</keyword>
	<keyword>pharmacokinetics/dynamics</keyword>
	<keyword>ulcerative colitis</keyword>
</DOC>